Vaccines Save Lives - Be Part of the Discovery
Stanford Vaccine Research Program
Vaccines have provided some of the most significant advancements in public health, dramatically improving global health outcomes by preventing infectious diseases. Today, vaccine research is entering a dynamic phase characterized by rapid expansion and innovation, promising to revolutionize not only the prevention of infectious diseases but also the treatment of various non-infectious conditions.
Recent developments include groundbreaking approaches that leverage vaccine technology to prevent large-scale infectious disease or treat cancers and allergic diseases, showcasing the versatility of vaccines beyond their traditional applications.
Our Vision
To prevent infectious diseases through the integration of cutting-edge science and compassionate care.
Our Mission
We are dedicated to advancing the field of preventive medicine by conducting rigorous research in collaboration with local communities and industry partners. Our goal is to ensure that new preventive therapies, including vaccines and other forms of immunization are safe, effective, and accessible for both national and global populations.
Current Studies
Pfizer Pediatric COVID-19 Vaccine Study
The COVID-19 pandemic continues to evolve with new variants of SARS-CoV-2. These variants contain mutations of the COVID-19 spike protein, which makes it harder for the body's immune system to protect against these new variants. To improve protection against these variants, Pfizer-BioNTech has developed an updated formulation of the COVID-19 vaccine.
This study vaccine is designed to protect against newer variants and is currently authorized by the United States Food and Drug Administration for children at least six months of age. For this new Phase 2/3 Sub-Study, we will evaluate the safety and tolerability of 2 doses of BNT162b2 (Omi KP.2) in participants between the ages of 6 months to < 2 years. Participants will receive 2 doses of BNT162b2 (Omi KP.2) at 10 micrograms each.
Please click here for more information: Pfizer COVID-19 Vaccine Study
PIVOT STUDY - Comparison of High vs. Standard Dose Influenza Vaccines in Pediatric Solid Organ Transplant Recipients
The purpose of this study is to compare influenza vacccine immunogenicity and safety between pediatric solid organ transplant recipients receiving two doses of High Dose Inactivated Influenza Vaccine (HD-IIV) or two doses of Stanford Dose Inactivated Influenza Vaccine (SD-IIV) over the course of one influenza season.
This study is a Phase 2, prospective, multi-center, double-blind randomized controlled clinical trial with 312 pediatric heart, liver and/or kidney transplant recipients.
Patients will be randomized (1:1) to receive two doses (separated by 4 weeks) of either HD-IIV or SD-IIV between 1 and 23 months post-transplantation. Eight sites across the United States are participating in this study, and the total study duration is approximately 3 years.
Please click here for more information: PIVOT STUDY
